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New options for the anemia of chronic
kidney disease
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Anemia is a common complication of chronic kidney
disease. Use of erythropoiesis-stimulating agents (ESA) has
been a mainstay of treatment since 1990. A series of large
trials demonstrated that ESAs have serious safety
problems, including increasing cardiovascular and
thrombotic events, and death. Analyses suggest high
pharmacologic doses of ESAs, rather than the highly
achieved hemoglobin, may mediate harm. Hypoxia-
inducible factor (HIF) activators stimulate endogenous
erythropoietin production and enhance iron availability. In
early clinical trials, these oral agents appear to be capable
of replacing ESA therapy and minimizing the need for i.v.
iron therapy for chronic kidney disease–related anemia,
while having other potentially advantageous actions. Large
phase 3 trials are underway with several HIF activators. This
commentary reviews trends in anemia management, the
safety issues related to our present therapies, the role of
HIF in regulating erythropoiesis, and the diverse actions of
HIF activators.
Kidney International Supplements (2017) 7, 157–163; https://doi.org/
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A nemia is a common complication in patients withchronic kidney disease (CKD), developing graduallyand increasing in severity as kidney disease
progresses.1 Anemia is associated with poor outcomes,
including higher mortality in patients with end-stage renal
disease (ESRD)2 and in those with non–dialysis-dependent
CKD.3 The major cause of anemia in CKD is a relative deﬁ-
ciency in erythropoietin (EPO) production,4 although the
complex clinical picture of most patients with CKD
frequently includes additional conditions contributing to the
development of anemia, such as inﬂammation and iron
deﬁciency. Until approximately 1990, anemia of CKD, espe-
cially in patients with ESRD, was managed with oral and
occasional i.v. iron administration, occasional use of andro-
gens, and blood transfusions for the severely anemic. Trans-
fusion complications included transfusion reactions,
sensitization, and iron overload.5 This resulted in lower he-
moglobin levels in patients with ESRD until pharmacologic
replacement of EPO with Epoetin in 1989 revolutionized the
approach to CKD-related anemia.
The prevalence of anemia (hemoglobin #12 g/dl) is high
(47.7%) in patients with nondialysis CKD and increases as
CKD progresses, being present in approximately 42% of
patients with stage 3 CKD, increasing to approximately 76%
in stage 5 CKD.6 The incidence of more severe anemia
(hemoglobin #10 g/dl), which is the treatment level
described in the package insert of erythropoiesis-stimulating
agents (ESAs), is less common: 5.6% prevalence in stage 3
CKD and 27.2% in stage 5 nondialysis CKD.7 Even though
anemia is very common in patients with advanced CKD,
relatively few of these patients receive treatment for it: among
patients with CKD stages 4 and 5, only 20% and 42%,
respectively, were on any treatment for anemia deﬁned using
gender-speciﬁc thresholds (<12 g/dl for female patients
and <13 g/dl for male patients).7
Anemia treatment trends in CKD have shown a secular
trend, perhaps as a result of clinical trials changing clinical
practices and changes in the regulatory environment.
Hemoglobin levels reported in patients initiating chronic
dialysis peaked at the end of 2006 in the United States at
approximately 10.5 g/dl in ESA-treated patients with CKD,
and approximately 10.0 in the remaining patients. Subse-
quently, mean hemoglobin has fallen steadily in these groups
and is approximately 9.5 g/dl in 2013 (Figure 1). This decline
comes in the wake of clinical trials showing no beneﬁt or even
harm from normalizing hemoglobin with ESA therapy.8
Correspondence: Daniel W. Coyne, Nephrology/Internal Medicine, Division
of Renal Diseases, Washington University School of Medicine, 660 S. Euclid
Ave. Campus Box 8129, St. Louis, Missouri, 63128 USA. E-mail:
dcoyne@wustl.edu
www.kisupplements.org r ev i ew
Kidney International Supplements (2017) 7, 157–163 157
Similar to the trends seen in hemoglobin concentration, ESA
use before starting dialysis has also fallen since 2006 and is
now below 15% utilization in the United States (Figure 2).8
Use of i.v. iron, in contrast, increased in dialysis patients,
with mean ferritin levels steadily increasing. Nondialysis CKD
and patients on dialysis have disordered iron metabolism due
to increases in hepcidin, the regulator of iron absorption and
release from reticuloendothelial cells. Clinically, physicians
have compensated for this disordered iron metabolism by
administering i.v. iron, but this may have adverse long-term
effects due iron increasing oxidative stress.
In addition to the trends observed in predialysis patients,
decreases in hemoglobin levels and ESA dose have also been
observed in dialysis patients. The average ESA dose in the
United States is now approximately 8000 units per week.9
Due to a more conservative approach to ESA therapy in
the past decade, a concomitant rise in blood transfusions
from approximately 2.5% to 3.0% has also been observed.
Some increase in transfusion rates may reﬂect appropriate
clinical decisions to avoid ESAs in some patients, such as
those with cancer or history of strokes, but the concern re-
mains that increased transfusions may have adverse effects,
especially among transplant-eligible patients. In summary,
disordered iron metabolism and EPO insufﬁciency contribute
to anemia in CKD, whereas treatment of anemia across the
CKD stages is less frequent and less aggressive, resulting in
lower hemoglobin levels and higher transfusion rates. The
growing concerns about the safety of ESA products are a
major driver in the shift toward worsening anemia in patients
with CKD.
Pathophysiology and epidemiology of anemia of CKD
Before the ESA era, patients with CKD and particularly
dialysis patients were routinely maintained at a low hemato-
crit level because interventions available to clinicians were
relatively ineffective. During this time, anemia therapy
consisted of iron supplements, androgen therapy, and blood
transfusions; however, there were predictable complications
to these interventions, including iron overload, infections,
allosensitization, and cardiovascular complications. The
therapy of anemia of CKD was revolutionized with the
introduction of Epoetin, the ﬁrst ESA, in 1989. This led to a
major reduction in the burden of illness suffered by patients
with CKD. In particular, ESA use led to the virtual elimina-
tion of patients with transfusion-dependent anemia.
Notwithstanding the major advancement of ESA therapy, its
therapeutic application can be considered to be unphysio-
logical regarding the dose, timing, and mode of administra-
tion. The early therapeutic paradigm for ESA had been to
administer high doses, which were then escalated every 2 to 4
weeks if a desired increase in hemoglobin concentration was
not achieved. This strategy ran counter to the human body’s
natural response to anemia, which is a short-term rise in
endogenous EPO levels (Figure 3), and likely increases the
possibility of signiﬁcant toxicities.10
Figure 1 | Changes in initial hemoglobin in US incident dialysis
patients. Adapted from the USRDS (US Renal Data System) Annual
Report, Volume 2, 2014. ESA, erythropoiesis-stimulating agents; Hgb,
hemoglobin.
Figure 2 | Changes in ESA use before initiation of dialysis in US
patients. Adapted from the USRDS (US Renal Data System) Annual
Report, Volume 2, 2014. ESA, erythropoiesis-stimulating agents.
Figure 3 | Epoetin concentration-time proﬁle following 2-unit
phlebotomy in normal male volunteers. The shaded area reﬂects
the 95% conﬁdence interval of the data. The arrows pointing right
show the baseline and post-phlebotomy hemoglobin values, while
the dotted line and arrow highlights that erythropoietin levels are still
above baseline 14 days after phlebotomy. Adapted with permission
from Fishbane S, Besarab A. Mechanism of increased mortality risk
with erythropoietin treatment to higher hemoglobin targets. Clin J
Am Soc Nephrol. 2007;2:1274–1282.10 Copyright ª American Society
of Nephrology. Hb, hemoglobin; RBC, red blood cell.
r ev i ew DW Coyne et al.: New options for the anemia of CKD
158 Kidney International Supplements (2017) 7, 157–163
The risks associated with ESA therapy are highlighted in 3
pivotal clinical trials. The ﬁrst prospective randomized trial to
assess the possibility of beneﬁts in normalizing blood
hemoglobin concentration with ESA therapy was the US
Normal Hematocrit trial, published in 1998.11,12 A total of
1265 patients on chronic dialysis were randomized into 2
groups with different target hematocrits (30% vs. 42%), and
followed until the development of the composite primary
endpoint of death or ﬁrst nonfatal myocardial infarction. The
study was prematurely halted due to a higher proportion of
patients in the higher hematocrit target group reaching the
primary endpoint, thus obviating the possibility of any beneﬁt
in “normalizing” the hematocrit and suggesting that treat-
ment with ESA to a normal hematocrit target may in fact be
detrimental. In addition to the primary endpoint, other
clinical endpoints, such as vascular access thrombosis, was
also signiﬁcantly increased, suggesting additional harmful
effects from the normal hematocrit treatment paradigm.
The 2006 Correction of Hemoglobin and Outcomes in
Renal Insufﬁciency trial was the next large randomized
controlled clinical trial designed to assess the effect of
different hemoglobin treatment targets (11.3 g/dl vs. 13.5
g/dl) on clinical events in 1432 patients with CKD stages 3
and 4.13 The group assigned to the higher hemoglobin target
experienced a signiﬁcantly higher rate of the composite
primary endpoint (congestive heart failure, hospitalizations,
stroke, or myocardial infarction) compared with the
low-target group, and there was no difference between groups
in quality-of-life scores.
The most recent large trial to assess the risks and beneﬁts
of ESA therapy was the 2009 Trial to Reduce Cardiovascular
Events with Aranesp Therapy trial, which randomized 4038
patients with type 2 diabetes mellitus and CKD stage 3 or 4 to
darbepoetin or placebo injections. The hemoglobin target was
13.0 g/dl. The median follow-up was 29.1 months. The
darbepoetin-treated arm did not show any reduction in the
primary endpoint (death, nonfatal myocardial infarction or
stroke, heart failure, or unstable angina), and experienced
signiﬁcantly more strokes (hazard ratio 1.92; 95% conﬁdence
interval, 1.68–2.38), venous thromboembolic events, arterial
thromboembolic events, and deaths from recurrent cancer
compared with the placebo arm.14 The only beneﬁts observed
from darbepoetin therapy were fewer transfusions and a
modest improvement in patient-reported fatigue.
For each of these studies, the hypothesis was that giving
ESAs and achieving a higher hematocrit or hemoglobin would
bring signiﬁcant clinical beneﬁts, although potential compli-
cations associated with the use of ESAs were already known or
suspected. Analyses of the major trial results have suggested
that the high ESA doses administered, rather than the speciﬁc
hemoglobin target, may be a major mediator of harm,
although a higher target leads to higher overall ESA doses.
During the early days, the use of ESAs in dialysis was asso-
ciated with hypertension, seizures, and vascular access
thrombosis. Subsequently, usage of ESAs was also linked to
hemoglobin “overshooting,” ESA-resistance, hemoglobin
cycling, strokes, and associations with cancer. There are
several proposed mechanisms of ESA toxicity (Figure 4),
which are to some extent masked by the difﬁculty in detecting
hypertension due to ESAs and the high underlying risk of
death due to cardiovascular events and possibly even
neoplasia in dialysis patients.
These toxicities may be mediated by one or more of the
several nonerythropoietic actions of high levels of EPO. The
appearance of hypertension could be related to increases in
renin-angiotensin-aldosterone system activation, asymmetric
dimethylarginine, thromboxane, and vascular smooth muscle
cell calcium concentration, and a decrease in prostacyclin,
leading to reductions in nitric oxide. The risk of thrombosis is
likely mediated through an increase in platelet production
and activity along with increases in Von Willebrand factor and
plasminogen activator inhibitor-1, whereas tumor growth and
vascular remodeling could be a result of vascular smooth
muscle cell and EC proliferation and angiogenesis. Overall,
targeting higher hemoglobin concentrations in patients with
CKD or ESRD is associated with increased risk of all-cause
mortality (risk ratio 1.17; 95% conﬁdence interval,
1.01–1.35; P ¼ 0$031), risk of arteriovenous access throm-
bosis (1.34; 1.16–1.54; P ¼ 0.0001), and higher risk of poorly
controlled blood pressure (1.27; 1.08–1.50; P ¼ 0.004).15
The current pattern of anemia management in CKD is
characterized by fewer patients being treated with ESA and
more patients receiving oral and i.v. iron. However, this
approach is still unphysiological and suboptimal, as there are
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Figure 4 | Potential mechanism of increased cardiovascular risk
with higher hemoglobin targets in ESA studies. Adapted with
permission from Fishbane S, Besarab A. Mechanism of increased
mortality risk with erythropoietin treatment to higher hemoglobin
targets. Clin J Am Soc Nephrol. 2007;2:1274–1282.10 Copyright ª
American Society of Nephrology. ESA, erythropoiesis-stimulating
agents; HD, hemodialysis.
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signiﬁcant concerns about the long-term beneﬁts of an
anemia management strategy that centers on iron adminis-
tration in often supraphysiologic doses. Potential complica-
tions include allergic reactions, infectious risks, and
long-term complications related to the induction of oxida-
tive stress, such as kidney injury leading to worsened renal
outcomes in patients with CKD.16 The lack of long-term
clinical trials assessing clinical outcomes associated with
various iron administration strategies makes it difﬁcult to
determine whether or not the current therapeutic paradigms
of i.v. iron administration in dialysis patients are safe, and
leaves many unanswered questions about what the best
approach should be for the optimization of iron homeostasis
in CKD. The more desirable approach moving forward is the
use of a more physiological strategy that has a gentle,
conﬁgurable correction and maintenance of hematocrit.
Anemia in CKD: changing treatment paradigms
As discussed previously, the currently available treatment
options for anemia of CKD and ESRD have signiﬁcant limi-
tations. The circulating levels of EPO required to stimulate
erythropoiesis is 7 to 30 mU/ml, with higher levels required in
patients with CKD and ESRD due to shortened red cell
survival. The unphysiologic administration of high-dose ESA
for anemia of CKD and ESRD can result in EPO levels as high
as 700 mU/ml, which is suspected to account for at least some
of the harm observed in the randomized trials. One treatment
strategy that may improve outcomes is to design interventions
that stimulate intermittent increases in endogenous EPO
levels, instead of use of high pharmacologic doses of ESAs.
EPO is a proliferation and maturation factor produced in
response to tissue hypoxia, as a result of complex regulatory
mechanisms,17–20 which were not yet fully understood at the
time when EPO was ﬁrst used therapeutically. Ninety percent
of all EPO produced in the body originates from the
kidneys and approximately 10% is produced by the liver.21
Kidney-derived EPO is produced by cortical peritubular
ﬁbroblasts located near the proximal tubular cells in the outer
medulla and inner cortex in the kidney. This production is
expanded into the outer cortex in response to hypoxia and
anemia, a region that is especially susceptible to hypoxia.
Indeed, tissue hypoxia is the pivotal factor that increases EPO
production as a ﬁnal step in a signal transduction pathway
involving several proteins, among which hypoxia-inducible
factors (HIFs) play a central role (vide infra).18
HIFs are proteins that play a pivotal role in the signal
transduction leading to EPO production.22 The HIF complex
consists of either HIF-1a or an oxygen-sensitive HIF-2a
subunit that associates with a constitutively expressed HIF-1b
subunit.22 Human renal ﬁbroblasts, under hypoxic condi-
tions, activate only HIF-2a and not HIF-1a. HIF-2a, in the
absence of hypoxia, is hydroxylated at 2-proline residues by
prolyl-hydroxylases, which mark the HIF-2a for binding by
von Hippel Lindau protein and subsequently for ubiquitina-
tion and proteasomal degradation.23 Prolyl-hydroxylase 2 has
been identiﬁed as the key enzyme that regulates HIF-2a
stability; prolyl-hydroxylase 2 has also been identiﬁed in
mutations leading to erythrocytosis.24 HIF-2a, in hypoxic
states, is not hydroxylated due to inhibition of prolyl-
hydroxylase and hence forms a heterodimer with HIF-1b
that translocates to the nucleus and binds to the hypoxia
response element of EPO and induces EPO transcription.
Prolyl-hydroxylase 2 enzymes have a wide range of intracel-
lular functions and targets, which include various genes
involved in erythropoiesis, including those for EPO, EPO
receptor, and proteins promoting iron absorption, iron
transport, and heme synthesis (Figure 5).
HIF-prolyl-hydroxylase 2 inhibitors or HIF stabilizers
represent a novel therapeutic intervention in the future
management of anemia.25 HIF stabilizers inhibit the
prolyl-hydroxylase enzyme leading to increased levels of HIF
and thus increased production of endogenous EPO. In the
ﬁrst study to show the proof of concept of this therapeutic
intervention, patients with normal kidneys and patients on
hemodialysis (including anephric patients who were analyzed
separately) received an HIF stabilizer with subsequent
measurement of plasma EPO.26 EPO levels increased after
administration of the HIF stabilizing agent, with an exag-
gerated response in plasma EPO in the nephric hemodialysis
patients. The anephric hemodialysis patients still had an
increase in EPO but not as exaggerated as the nephric
patients, possibly a result of hepatic EPO production.26
There are currently 4 HIF stabilizers that are in phase 2/3
clinical trials (roxadustat, daprodustat, vadadustat, and
molidustat), and all are orally administered agents (Table 1).
In a phase 2 clinical trial of roxadustat, 4 different groups of
patients were evaluated: hemodialysis receiving no iron,
hemodialysis receiving oral iron, hemodialysis receiving
i.v. iron, and peritoneal dialysis receiving oral iron (see
Figure 6).27 Oral iron in hemodialysis patients receiving
conventional ESA therapy has been shown to be no better
than no iron due to blockade of iron absorption by high
hepcidin levels. Hemoglobin levels increased in all the groups,
including the patients who did not receive iron; however, the
response in this group was less than in the patients who were
receiving i.v. and oral iron, suggesting HIF stabilizers enhance
iron availability. In another phase 2 dose-ﬁnding trial of
daprodustat examining nondialysis patients with CKD and
hemodialysis patients, 5 mg of daprodustat resulted in an
increase in hemoglobin concentration in nondialysis patients
with CKD, and was maintained at the level of control group
(which received ESA) in hemodialysis patients.28 Vadadustat
was studied in a 20-week double-blind, randomized, placebo-
controlled phase 2b study in nondialysis-dependent patients
with CKD.29 Similar to the other agents, there was a signiﬁ-
cant increase in hemoglobin concentration compared with
placebo. Signiﬁcant increases in both reticulocytes and total
iron-binding capacity and signiﬁcant decreases in both serum
hepcidin and ferritin levels were observed in patients on
vadadustat compared with placebo.29 Finally, molidustat was
studied in a phase 2 clinical trial, also showing a
dose-dependent increase in hemoglobin levels.30
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There are several important differences between HIF
stabilizers and ESAs in their effects on circulating EPO levels.
HIF stabilizers increase hemoglobin with much lower levels of
circulating EPO,31 thus eliminating the risk of patient expo-
sure to such high levels. In addition, the roxadustat study
indicated that patients supplemented with oral and i.v. iron
had the exact same response rates to these treatments, in
contradistinction of what has been previously described in
ESA studies whereby patients receiving i.v. iron typically had
better responses.27 One potential explanation for this obser-
vation is that HIF stabilizing agents appear to lower hepcidin
levels, which results in increased iron availability and
increased reticulocyte hemoglobin content, as demonstrated
in patients treated with roxadustat when compared with
patients receiving EPO. The effects of HIF stabilizers on
hepcidin levels may also explain why the hemoglobin
response seen with this new class of drugs is independent of
background inﬂammation. In contrast, patients with
inﬂammation typically require higher ESA doses and are less
likely to achieve target hemoglobin.
In addition to the fundamentally different mechanisms of
action that mediate the effect of HIF activators on hemo-
globin production, there are additional effects of these
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Figure 5 | Hypoxia-inducible factor (HIF) gene targets. Reprinted from Schoﬁeld CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev
Mol Cell Biol. 2004;5:343–354, by permission from Macmillan Publishers Ltd.
Table 1 | Hypoxia-inducible factor stabilizers under
development for treatment of anemia in chronic kidney
disease
Company Molecule Drug name
Phase
of development
FibroGen
Astellas
AstraZeneca
FG-4592 Roxadustat Phase 3
GlaxoSmithKline GSK 1278863 Daprodustat Phase 3
Akebia AKB-6548 Vadadustat Phase 3
Bayer BAY 85–3934 Molidustat Phase 2/3
Japan Tobacco Inc JTZ-951 Phase 1
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agents that are independent of EPO production and the
regulation of iron metabolism, some of which may be
beneﬁcial (e.g., alleviation of ischemic injury32 and beneﬁ-
cial effects in diabetic nephropathy33), but others that may
be harmful (such as its effects on angiogenesis34 and glucose
metabolism35). Currently there are no early signs of
concerns regarding adverse effects in the available clinical
trials. Furthermore, living at high altitudes, which results in
physiologic changes similar to the effects of HIF activators
(e.g., reduction in EPO requirements and resistance), is
associated with lower all-cause mortality, lower cancer rates,
and fewer cardiac events in dialysis patients.36–40 Never-
theless, more extensive evaluations are warranted to ensure
the safety of HIF activators. There are several phase 3 trials
of HIF activator agents. They uniformly include thousands
of patients and hard safety endpoints, which should inform
us about the beneﬁts and risks of these agents versus ESA
therapy and placebo.
Summary
In summary, the ﬁeld of anemia therapy in CKD and ESRD
has progressed from one with very limited options in the
pre-ESA era to one in which novel agents are developed to
induce therapeutic effects that more closely mimic the
body’s own responses to hypoxia, raising hope that the
complications caused by the prevailing ESA-based para-
digms can be eliminated. The new class of orally adminis-
tered HIF stabilizers that is under clinical development
mimics hypoxia, resulting in the upregulation of EPO gene
expression, and in an increase in both hemoglobin
concentration and iron transport proteins. Because these
agents may upregulate other hypoxia-sensitive genes that are
involved in angiogenesis and tumor growth, their long-term
safety will need to be proven.
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